Research Publications

Links to some of our previous studies

Please see below sample of published research results from some of the studies that the Royal Cornwall Hospitals Trust have been involved in. We are aiming to increase the number available on this webpage in the future.

Please note there is often a significant time lag between the end of patient participation in a study and the availability of the results.

Cancer

• Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
• Talapro 2- advanced prostate cancer: Royal Cornwall Hospitals NHS Trust contributes to trial showing hope in extending survival for prostate cancer patients | Royal Cornwall Hospitals NHS Trust
• Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI
• MONITOR-UK: An initial analysis of a multi-centre, observational study of maintenance niraparib in ovarian cancer
• First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): Lung Cancer Research Study Publishes Results Showing Improved Survival Rates | Royal Cornwall Hospitals NHS Trust
• A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
• Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
• Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction
• Genomic and intrinsic subtype correlates of serum thymidine kinase activity in patients with metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial

Cardiology

• Acute coronary syndrome rule-out strategies in the emergency department
• DAPA: Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.

COVID

• Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): RCHT led the way in groundbreaking SUPERNOVA trial | Royal Cornwall Hospitals NHS Trust
• Recovery: Results.

Emergency Medicine

• Subarachnoid Haemorrhage in the ED (SHED)

Gynaecology

• Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation
• Proper Understanding of Recurrent Stress Urinary Incontinence Treatment in women (PURSUIT): A Randomised Controlled Trial of Endoscopic and Surgical Treatment

Haematology

• FLAIR: Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Hepatology

• Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)

Oncology

• A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results.
• Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasia
• Developing a central database and virtual biobank for rare gynaecological cancers in the UK: Rango (rare neoplasms of gynaecological origin)
• c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
• Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
• Parsifal- Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer.
• Testosterone suppression plus enzlutamide vs testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
• PALMIRA: PALMIRA Unable to Answer Lingering Questions About CDK4/6 Resistance in Metastatic Breast Cancer.
• Phergain: 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).
• NATALEE: Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.
• Interlace: Better use of existing drugs increases cervical cancer survival and reduces recurrence.
• Godrevy: ‘Godrevy Project’: virtual reality for symptom control and well-being in oncology and palliative care – a non-randomised pre-post interventional trial.
• Monitor: 52P MONITOR-UK: An initial analysis of a multi-centre, observational study of maintenance niraparib in ovarian cancer.
• REACT Cemi: Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab).

Orthopaedics

• Advice only versus advice and a physiotherapy programme for acute traumatic anterior shoulder dislocation: the ARTISAN RCT
• Dupuytren’s Interventions Surgery vs. Collagenase
• Rehabilitation versus surgical reconstruction for non-acute anterior cruciate ligament injury (ACL SNNAP): a pragmatic randomised controlled trial

Paediatrics

• Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
• NAPPA: The Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA): investigating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin pharmacokinetics from birth to adolescence
• CASAP: Children’s Acute Surgical Abdomen Programme (CASAP)

Pharmacy

• RIPAL: P09 Non-allergist Removal of Incorrect Penicillin Allergy Labels (RIPAL) in a UK hospital

Women’s Health & Obstetrics

• Induction of labour for predicted macrosomia: study protocol for the ‘Big Baby’ randomised controlled trial:
• Two-year outcomes following a randomised platelet transfusion trial in preterm infants
• Pregnancy and Neonatal Outcomes of COVID-19 (PAN-COVID)

NHS Staff Research

• Hair today, gone tomorrow: How personal protective equipment guidance changed doctor’s facial hair during the COVID‐19 pandemic

Radiography

• An artificial intelligence deep learning model for identification of small bowel obstruction on plain abdominal radiographs

Stroke

• Stroke Audit Machine Learning (SAMueL 2)
• Optimas

Vascular

• BASIL2: A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.
• Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT